Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kalaris Therapeutics Inc.

2.69
+0.01000.37%
Post-market: 2.690.00000.00%16:00 EDT
Volume:52.81K
Turnover:140.50K
Market Cap:50.31M
PE:-0.26
High:2.75
Open:2.72
Low:2.56
Close:2.68
Loading ...

Company Profile

Company Name:
Kalaris Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
14
Office Location:
628 Middlefield Road,Palo Alto,California,United States
Zip Code:
94301
Phone:
- -
Fax:
- -
Introduction:
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Directors

Name
Position
Andrew Oxtoby
President and Chief Executive Officer and Director
David Hallal
Chairman
Anthony Adamis
Director
Leone Patterson
Director
Michael Dybbs
Director
Morana Jovan Embiricos
Director
Napoleone Ferrara
Director
Srinivas Akkaraju
Director

Shareholders

Name
Position
Andrew Oxtoby
President and Chief Executive Officer and Director
Brett Hagen
Chief Accounting Officer
Matthew Feinsod
Chief Medical Officer